These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 30400107)

  • 21. Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy.
    Valera E; Monzio Compagnoni G; Masliah E
    Neuropathol Appl Neurobiol; 2016 Feb; 42(1):95-106. PubMed ID: 26924723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of Passive Immunotherapies for Synucleinopathies.
    Bergström AL; Kallunki P; Fog K
    Mov Disord; 2016 Feb; 31(2):203-13. PubMed ID: 26704735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How should we be using biomarkers in trials of disease modification in Parkinson's disease?
    Vijiaratnam N; Foltynie T
    Brain; 2023 Dec; 146(12):4845-4869. PubMed ID: 37536279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α-Synuclein.
    Jensen PH; Schlossmacher MG; Stefanis L
    Mov Disord; 2023 Mar; 38(3):378-384. PubMed ID: 36645106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
    J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Search for a Peripheral Biopsy Indicator of α-Synuclein Pathology for Parkinson Disease.
    Lee JM; Derkinderen P; Kordower JH; Freeman R; Munoz DG; Kremer T; Zago W; Hutten SJ; Adler CH; Serrano GE; Beach TG
    J Neuropathol Exp Neurol; 2017 Jan; 76(1):2-15. PubMed ID: 28069931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An alpha-synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression.
    Yang L; Stewart T; Shi M; Pottiez G; Dator R; Wu R; Aro P; Schuster RJ; Ginghina C; Pan C; Gao Y; Qian W; Zabetian CP; Hu SC; Quinn JF; Zhang J
    Proteomics Clin Appl; 2017 Jul; 11(7-8):. PubMed ID: 28319654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. α-synuclein imaging: a critical need for Parkinson's disease research.
    Eberling JL; Dave KD; Frasier MA
    J Parkinsons Dis; 2013; 3(4):565-7. PubMed ID: 24192754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification.
    Ko WKD; Bezard E
    Exp Neurol; 2017 Dec; 298(Pt B):172-179. PubMed ID: 28764902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nitrated alpha-synuclein in minor salivary gland biopsies in Parkinson's disease.
    Ma LY; Gao LY; Li X; Ma HZ; Feng T
    Neurosci Lett; 2019 Jun; 704():45-49. PubMed ID: 30946930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker.
    Visanji NP; Marras C; Hazrati LN; Liu LW; Lang AE
    Mov Disord; 2014 Apr; 29(4):444-50. PubMed ID: 24375496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.
    Amer DA; Irvine GB; El-Agnaf OM
    Exp Brain Res; 2006 Aug; 173(2):223-33. PubMed ID: 16733698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lewy pathological study on α-synuclein in gastrointestinal tissues of prodromal Parkinson's disease.
    Lu QB; Zhu ZF; Zhang HP; Luo WF
    Eur Rev Med Pharmacol Sci; 2017 Apr; 21(7):1514-1521. PubMed ID: 28429355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of rodent models in advancing precision medicine for Parkinson's disease.
    Simons E; Fleming SM
    Handb Clin Neurol; 2023; 193():3-16. PubMed ID: 36803818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies.
    Moussaud S; Malany S; Mehta A; Vasile S; Smith LH; McLean PJ
    Expert Opin Ther Targets; 2015 May; 19(5):589-603. PubMed ID: 25785645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
    Oueslati A; Fournier M; Lashuel HA
    Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
    Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM
    Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
    Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
    Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting α-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics.
    Savitt D; Jankovic J
    Drugs; 2019 Jun; 79(8):797-810. PubMed ID: 30982161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic approaches to target alpha-synuclein pathology.
    Brundin P; Dave KD; Kordower JH
    Exp Neurol; 2017 Dec; 298(Pt B):225-235. PubMed ID: 28987463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.